Insider Selling: Marrone Bio Innovations, Inc. (NASDAQ:MBII) Director Sells 21,009 Shares of Stock

Marrone Bio Innovations, Inc. (NASDAQ:MBIIGet Rating) Director Pamela G. Marrone sold 21,009 shares of the firm’s stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $1.15, for a total transaction of $24,160.35. Following the transaction, the director now owns 2,199,626 shares of the company’s stock, valued at approximately $2,529,569.90. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

NASDAQ MBII traded down $0.07 during mid-day trading on Wednesday, hitting $1.09. The company’s stock had a trading volume of 438,704 shares, compared to its average volume of 859,958. The company’s 50 day simple moving average is $1.03 and its 200 day simple moving average is $0.82. Marrone Bio Innovations, Inc. has a twelve month low of $0.55 and a twelve month high of $1.95. The company has a current ratio of 0.79, a quick ratio of 0.75 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $198.68 million, a price-to-earnings ratio of -9.08 and a beta of 0.36.

Marrone Bio Innovations (NASDAQ:MBIIGet Rating) last posted its quarterly earnings results on Wednesday, May 11th. The basic materials company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Marrone Bio Innovations had a negative net margin of 47.07% and a negative return on equity of 70.87%. During the same quarter last year, the company posted ($0.02) earnings per share. As a group, research analysts forecast that Marrone Bio Innovations, Inc. will post -0.05 EPS for the current year.

Several research analysts have issued reports on MBII shares. StockNews.com lowered shares of Marrone Bio Innovations from a “hold” rating to a “sell” rating in a report on Friday, May 13th. Canaccord Genuity Group lowered shares of Marrone Bio Innovations from a “buy” rating to a “hold” rating and lowered their price target for the stock from $2.00 to $1.30 in a report on Friday, March 18th. Finally, Zacks Investment Research raised shares of Marrone Bio Innovations from a “sell” rating to a “hold” rating in a research report on Friday, March 18th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.01.

A number of large investors have recently modified their holdings of MBII. Morgan Stanley lifted its stake in Marrone Bio Innovations by 391.8% during the 1st quarter. Morgan Stanley now owns 262,495 shares of the basic materials company’s stock valued at $549,000 after acquiring an additional 209,117 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Marrone Bio Innovations by 305.8% during the 2nd quarter. Wells Fargo & Company MN now owns 113,217 shares of the basic materials company’s stock valued at $188,000 after acquiring an additional 85,320 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Marrone Bio Innovations during the 3rd quarter worth $31,000. Barclays PLC raised its stake in shares of Marrone Bio Innovations by 44.4% during the 3rd quarter. Barclays PLC now owns 81,513 shares of the basic materials company’s stock worth $74,000 after purchasing an additional 25,075 shares during the period. Finally, IndexIQ Advisors LLC raised its stake in shares of Marrone Bio Innovations by 11.1% during the 3rd quarter. IndexIQ Advisors LLC now owns 215,119 shares of the basic materials company’s stock worth $194,000 after purchasing an additional 21,548 shares during the period. Institutional investors and hedge funds own 68.42% of the company’s stock.

Marrone Bio Innovations Company Profile (Get Rating)

Marrone Bio Innovations, Inc discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects.

Featured Stories

Insider Buying and Selling by Quarter for Marrone Bio Innovations (NASDAQ:MBII)

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.